PDX1 and neoplasm: Importantly, targeting PPY enhanced the efficacy of anti‐PD‐1 immunotherapy in KPC (KrasLSL‐G12D/+; Trp53LSL‐R172H/+; Pdx1‐Cre) mice, as evidenced by reduced tumor burden on PET‐CT imaging and improved survival.